Home › Calculator › NKTR Dividend Calculator 2026
NKTR Dividend Calculator 2026
No dividendHealthcareNektar Therapeutics · NASDAQ
Price: $37.22 · Annual div: None · Frequency: — · Payout ratio: N/A · Ex-div: —
Calculator settings
NKTR is not a dividend-focused stock
NKTR pays a very low or no dividend (Yield: 0.00%). This calculator is designed for income-producing assets. If your goal is passive income and compounding, you might want to look at these popular alternatives:
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
NKTR Dividend Yield
Nektar Therapeutics (NKTR) does not currently pay a regular dividend in our data, so its dividend yield is 0%.
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When NKTR pays your bills
Year your monthly dividend income covers each expense (based on current settings)
About Nektar Therapeutics (NKTR) — Dividend Analysis 2026
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.
NKTR Dividend & DRIP — Frequently Asked Questions
Does NKTR pay a dividend?
No. Nektar Therapeutics (NKTR) has not paid a regular dividend in the last 12 months in our data, so its dividend yield is 0% and it produces no dividend income.
How can I get dividend income instead of NKTR?
Dividend ETFs such as SCHD, VYM or JEPI pay regular income. Open their DRIP calculators to see what $10,000 would earn per month and how reinvesting grows it.
Does NKTR have a DRIP (dividend reinvestment plan)?
A DRIP reinvests dividends into new shares. NKTR has no regular dividend in our data, so there is nothing to reinvest.
Stocks similar to NKTR
Forward dividend yield from the latest data · open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full NKTR DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open NKTR position with:
🌍 NKTR Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold NKTR.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 0.00% | -2.80% | $0 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 0.00% | -2.80% | $0 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 0.00% | -2.80% | $0 / yr |
| 🇬🇧 UK ISA | 0% | 0.00% | -2.80% | $0 / yr |
| 🇬🇧 UK Taxable | 8.75% | 0.00% | -2.80% | $0 / yr |
| 🇨🇦 TFSA | 0% | 0.00% | -2.80% | $0 / yr |
| 🇨🇦 CA Taxable | 25% | 0.00% | -2.80% | $0 / yr |
| 🇦🇺 Super (pension) | 15% | 0.00% | -2.80% | $0 / yr |
| 🇦🇺 AU Taxable | 30% | 0.00% | -2.80% | $0 / yr |
| 🇩🇪 DE Taxable | 26.375% | 0.00% | -2.80% | $0 / yr |
| 🇫🇷 FR Taxable | 30% | 0.00% | -2.80% | $0 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 NKTR Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
No dividend data available for this ticker.
Based on current dividend of $0.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 NKTR Dividend Payment Schedule
NKTR pays quarterly — 4 times per year. Ex-div: —.
📊 NKTR vs Healthcare Benchmarks
How NKTR compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for NKTR sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ NKTR Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2026-09-23 | 2,000 | — | — | ||
| A-Award | 2026-09-23 | 4,000 | $57.66 | $230.6K | ||
| A-Award | 2026-09-23 | 2,000 | — | — | ||
| A-Award | 2026-09-23 | 4,000 | $57.66 | $230.6K | ||
| A-Award | 2026-09-23 | 2,000 | — | — | ||
| A-Award | 2026-09-23 | 4,000 | $57.66 | $230.6K | ||
| A-Award | 2026-09-23 | 4,000 | $57.66 | $230.6K | ||
| A-Award | 2026-09-23 | 2,000 | — | — | ||
| A-Award | 2026-09-23 | 2,000 | — | — | ||
| A-Award | 2026-09-23 | 4,000 | $57.66 | $230.6K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Peer Group
Similar companies in the same sectorCompare NKTR with peers: NKTR vs AMLX · NKTR vs ATAI · NKTR vs ELVN
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Geographic Revenue Breakdown
Where NKTR earns its moneyRevenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the NKTR dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Nektar Therapeutics (NKTR) is currently trading at $37.22, 66% below its 52-week high. It does not currently pay a regular dividend.
Does NKTR Pay a Dividend? Nektar Therapeutics Dividend Status
Nektar Therapeutics (NKTR) is a healthcare stock trading at $37.22. It does not currently pay a regular dividend in our data, so it produces no dividend income and DRIP reinvestment does not apply. Investors seeking income often look at dividend ETFs such as SCHD, VYM or JEPI instead.
- Without a dividend, returns depend entirely on the share price.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest NKTR News
LiveNews aggregated from public sources via Finnhub & RSS. For informational purposes only.
Projected your NKTR DRIP returns?
If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.